Previously Established Therapeutic Target Gene for Breast Cancer Might Not Be Viable

Previously Established Therapeutic Target Gene for Breast Cancer Might Not Be Viable
shutterstock_88169086Researchers at Stanford University and Stanford University School of Medicine recently published in the journal Genome Medicine findings revealing that the gene PIK3CA, which has been associated with breast cancer and been used as a target in cancer drug development, might not be as promising as initially thought. The study is entitled “Cell-lineage heterogeneity and driver mutation recurrence in pre-invasive breast neoplasia.” Approximately 20% of all breast cancers exhibit mutations in a gene called PIK3CA, accounting for the second most frequent gene mutation found in breast cancer. However, mutations in PIK3CA have also been reported in neoplastic lesions, pre-cancerous growths considered benign (not considered tumors), and those that have not invaded the neighboring tissue. In order to better understand these neoplastic growths and their possible link to breast cancer development, the research team sequenced the genes present in breast tissue from six women who had undergone a mastectomy (partial or complete surgical removal of the breast). A total of 66 samples were analyzed, including 18 carcinomas and 34 neoplastic lesions. The researchers created phy
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.